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1. Objective 
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The aim of this thesis is to summarize the most important mechanisms that can 
contribute to the development of a resistance to platinum drugs (i.e. clinically used 
cisplatin, carboplatin and oxaliplatin; this essay does not consider agents that are not 
in clinical use at this time). 
This work focuses especially on the resistance caused by decreased influx and 
increased efflux of platinum drugs (diminished accumulation), detoxification by 
glutathione and metallothionein, improved repair of DNA lesions and enhanced 
tolerance to DNA-Pt adducts. For each of these intracellular mechanisms of resistance 
this essay tries to describe presumptive mechanism of action, importance in clinic and 
briefly assessed possibilities of circumventing resistance. 
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2. Introduction 
  
7 
 
Although the first platinum drug, cisplatin [cis-diamminedichlorplatinum (II)] (Figure 
1) was initially described by M. Peyrone in 1845 [1], its biological activity was 
discovered more than 100 years later. In 1965, Rosenberg and co-workers reported 
that the cytostatic effect induced by electric fields on cultures of Escherichia Coli was 
due to the formation of cisplatin and its corresponding tetrachloroplatinum(IV) analog 
by electrochemical reactions on platinum electrodes [2]. First preclinical pharmacology 
studies in 1969 have approved cisplatin antitumor properties [3]. Cisplatin is now in 
widespread use for the treatment of variety of human malignancies. However, many 
tumors are intrinsically resistant, and the development of acquired resistance during 
the course of treatment of initially sensitive tumors is a common occurrence that 
constitutes a major obstacle to the curative use of this drug [4]. Another important 
obstacle is severe side effects of which nephrotoxicity and peripheral neurotoxicity are 
the most serious [5, 6] (Figure 2) and limit its curative potential. Nephrotoxicity is 
primarily due to uptake by the proximal tubule cells of the nephron, with uptake by 
other cells having a lesser effect [6]. Nephrotoxicity has largely been controlled by 
diuretics and pre-hydratation of patients, such that neurotoxicity has now become the 
dose-limiting side effect.  These pharmacological disadvantages stimulated the search 
for other platinum analogues with improved pharmacological properties. A large 
number of platinum analogues have been synthesized since cisplatin cytostatic activity 
was discovered but only a few are in clinical use. 
Carboplatin [cis-diammine-1, 1-cyclobutanedicarboxylate platinum(II)] (Figure 1) is 
a second generation analogue. It has the same mechanism of action as cisplatin, is 
cross-resistant and forms similar lesions on DNA. But in contrast to cisplatin dose-
limiting side effects - nephrotoxicity, neurotoxicity and ototoxicity - carboplatin alone 
shows a low incidence of nephrotoxicity because of its slower rate of conversion to 
active platinum aquo species [7] and is also notably less neurotoxic than cisplatin at 
conventional doses (but with similar sensory neuropathy occurring in approximately 
6% of patients). [8]. Its dose-limiting side effect is  myelosuppression, specifically 
neutropenia and thrombocytopenia [9] (Figure 2). Both agents (cisplatin and 
carboplatin) are used for many types of cancer, including ovarian, cervical, head and 
neck, non-small cell lung and lymphoma, though carboplatin is supplanting the use of 
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cisplatin for most ovarian tumors and for treatment of non-small cell lung carcinoma 
[10]. 
Oxaliplatin [trans-L-1,2-diaminocyclohexaneoxalate platinum(II)] (Figure 1) is 
another clinically used platinum based analogue. It contains a DACH carrier ligand 
(diaminocyclohexane) and perhaps for this, oxaliplatin has consistently demonstrated 
antitumor activity in cell lines with acquired cisplatin resistance and appear to be 
active in tumor types that are intrinsically resistant to cisplatin and carboplatin [11-13]. 
Oxaliplatin’s intrastrand cross-links are different and may account in part for its 
different spectrum of activity as reviewed in preclinical screen of National Cancer 
Institute [14]. Oxaliplatin was shown to have markedly different spectrum of activity to 
cisplatin and carboplatin [15]. In in vivo studies, oxaliplatin is active against breast, 
colon, and gastric cancer, renal cell carcinoma, and sarcoma [16]. It has also been 
tested against ovarian, lung, cervix, colon, and leukemia cell lines. Much like previous 
platinum drugs, likewise oxaliplatin has its side effects. The most common toxicity 
associated with oxaliplatin treatment is peripheral neuropathy, which ranges from 
acute and transient to a cumulative neuropathy [9]. Oxaliplatin is generally free of 
ototoxicity and nephrotoxicity, with only moderate isolated cases of neutropenia and 
thrombocytopenia [17].  
A number of analogues have failed over the years, some because unexpected 
toxicities (such as nephrotoxicity) and some because of no clear advantage over the 
remarkable toxicity reduction exemplified by carboplatin. Nevertheless, a number of 
platinum analogues (e.g. satraplatin, transplatin, tetraplatin) and some formulations 
are currently undergoing study. How these new compounds differ mechanistically as 
well as pharmacologically from currently available platinum drugs should be the key to 
their future development [18].  
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Figure 1. The chemical structures of cisplatin, carboplatin and oxaliplatin. 
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Figure 2. Toxicities associated with the treatment with platinum drugs. The most common side 
effects associated with cisplatin treatment are ototoxicity, peripheral neuropathy, 
myelosuppression, and nephrotoxicity. Ototoxicity is notably higher in pediatric patients, while 
neuropathy is relatively more common in adult patients. The most common toxicity associated 
with carboplatin is myelosuppression, with rare cases of neurotoxicity and nephrotoxicity. 
Oxaliplatin most commonly causes neurotoxicity (Adopted from [9]). 
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3. Platinum drugs resistance 
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The development of resistance to platinum-based chemotherapy in the clinic is a 
major challenge for cancer chemotherapy [19]. Although the phenomenon of 
multidrug resistance against natural product drugs exemplified by the ATP-dependent 
efflux pump P-glycoprotein and other transporters is well characterized [20], the 
cellular responses that confer resistance to platinum complexes are multifactorial and 
less well understood [21, 22]. The generally accepted intracellular mechanisms by 
which cells acquire resistance to cisplatin and its congeners are (i) increased 
detoxification of drug by the thiols glutathione and metallothionein; (ii) improved 
repair of, and tolerance to, nuclear lesions, leading to a concomitant reduction in 
apoptosis; and (iii) diminished accumulation of platinum complexes [22, 23]. Overall, 
several factors may contribute to resistance (Table 1).   
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Table 1 - Mechanisms of resistance to platinum drugs (Adopted from [24]) 
Mechanism Contributing factor 
Impaired blood flow/drug delivery ↑ Tissue pressure ↑ Plasma fibrinogenb ↑ Blood viscosityb 
 
↓ Blood pressuree ↓ RBC deformabilityb 
 
 
Extracellular matrix/other factors ↑ Tissue pressure/↓ diffusion  ↑ γ-Glutamyltransferase 
 
 
↑ Fibronectin ↑ Type IV collagen ↑ Laminin 
 
Decreased drug uptake ↑ Cell membrane rigidity ↑ Sphingomyelin ↑ Cholesterol 
 
↑ NaClc  ↑ KClc ↑ Mannitolc 
 
↑ Extracellular pH ↑ Protein binding 
 
 
↓ Copper transporter CTR1 ↑ Copper ↓ CaCl2
c 
 
↓ Uptake concurrently of several 
factors 
Concurrent ↓ expression several 
transporters ↓ γ-Catenin 
 
Defective endocytosis/formation of 
endocytic recycling compartment 
↓ Small GTPases (rab5, rac1, rhoA) 
which regulate endocytosis 
 
 
Increased efflux ↑ Cu transporters ATP7A, -7B ↓ CuCl2c  ↑ Intracellular pH 
 
↑ MRP2/cMOAT/GSH-X pumpd ↑ MRP1d ↑ p-Glycoproteind 
 
↑ MVP/LRPd 
Abnormal sorting into exosomal 
pathway 
↑ Sequestration  
intracelluarly 
 
Increased detoxification ↑ GSH ↑ GSTd  ↑ GST-pi/GST-pi SNPse 
 
↑ γ-Glutamylcysteine synthase ↑ γ-Glutamyltransferase ↑ GSH peroxidase 
 
↑ Glutamate cysteine ligase ↑ GSH reductase ↑ Catalase 
 
↑ Dihydrodiol dehydrogenase ↑ Superoxide dismutase ↑ Metallothioneinsd,e 
 
Decreased drug binding ↑ Proton pumps ↑ Intracellular pH ↑ Extracellular pH 
 
↑ In cell cycle G1/ ↓ in G2/M ↑ Histone methylation 
 
 
Increased DNA repair 
↑ Nucleotide excision repair system 
(ERCC1 and XPF) ↑ XPAe ↑ BRCA1e 
 
Host ERCC1/XPD SNPse, ↑ Topoisomerase-II ↑ REV1 
 
↑ Base excision repair (DNA 
polymerase-βd, -zeta, and -eta) 
↑ Homologous recombination 
repair 
↑ DDB2 (damaged-DNA 
-binding-protein-2 
 
↑ DNA damage recognition protein 
HMG1 
  
 
Increased tolerance of DNA damage 
↓ DNA postreplicational mismatch 
repair ↓ hMLH1, hMSH2, hMSH6d  
↓ Non-homologous  
end-joining repair 
 
Decreased pro-apoptotic factors 
Down-regulation/↓ expression (p53, 
p53-binding-protein-2, Bax, Fas, 
caspases 8, 9, other) ↓ Activation (Fas, caspase 9) 
P53 mutation (with 
overexpression of a non-
functional protein)d,e 
 
Mitochondrial abnormalities P53 deletion 
 
 
Increased apoptosis inhibitors ↑ Bcl-2d,e ↑ Bcl-xLd,e ↑ Bfl-1/A1 
 
↑ Survivin Hypoxia (via ↑ Bcl-xL) ↑ FLIP 
 
↑ Xiap ↑ IAP-2 ↑ COX-2d,e 
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Altered mitochondria ↑ Fatty acid use for O2 consumption 
↑Mitochondrial-uncoupling-
protein-2 ↑ No. mitochondria 
 
↓ Membrane potential 
  
 
Increased chaperones ↑ HSP27d  ↑ HSP90-β ↑ HSP70 
 
↓ GRP78 
  
 
Altered cell signaling pathways ↑ E-cadherin ↑ EGF/EGFR Catenins: ↑ α & β / ↓ γ 
 
↑ Heregulin/ ↑ p21WAF1/CIP1 ↑ Her-2/neud  PTEN loss 
 
↑ PI3K ↑ AKT ↑ mTOR 
 
↑ MAPK signaling cascaded ↑ p110α ↑ Hyaluronan-CD44 
 
↑ c-Myc/c-Fos/c-Jun activation ↑ /Mutated ras ↑ c-cot 
 
↑ STAT1/STAT3/JAK2 ↑ PDE2 ↑ PKC-iota 
 
↑ Protein phosphatases 2A & 4 SRPK1 inactivation ↓ SAPK/JNK activation 
 
↓ p38 kinase activation ↓ IP3R1 ↓ HGF 
 
Transcription factors, cell cycle related factors, 
checkpoint kinases, etc. ↑ YB-1 ↑ CTF2 ↑ ATF4 
 
↑ ZNF143 ↑ mtTFA ↑ Ets-1 
 
↑ Zipper transcriptional factor ↑ AP-2 ↑ SKP2 
 
↑ NF-kappaBd  ↑ Cyclin D1 
 
 
↓ Chk1 ↓ Chk2 
 
 
↓ Telomerase mRNA expression ↓ Telomere length ↓ Telomerase activity 
 
Gene arrays: differential expression ↑ FN1 ↑ TOP2A ↑ LBR 
 
↑ ASS ↑ COL3A1 ↑ STK6 
 
↑ SGPP1 ↑ ITGAE ↑ PCNA 
 
↑ MDR1 ↑ MRP1 ↑ MRP2 
 
↑ CD55 ↑ PGK1 ↓ Caveolin 1 
 
Proteomic analyses: differential expression 
↑ HSP60/HSP90/heat-shock cognate 
71 kDa protein ↑ Calmodulin ↑ Calumenin 
 
↑ Peroxiredoxins PRX 2/PRX 6 ↑ GST ↑14-3-3 
 
↑ Voltage-dependent anion-selective 
channel-1 
  
 
Miscellaneous ↑ Ribosomal proteins RPS13, RPL23 Altered sphingolipid pathway 
Altered ganglioside  
expression 
 
Chromosomal abnormalities ↑ Splicing factor SPF45 ↑ Serum LDHd,e 
 
↑ Glucose utilizationf ↑ Lactate productionf ↑ LDH-5e,f 
 
↑ Golgi apparatus ↓ Microsatellite D6S1581 ↓ Pyruvate kinase M2 
a Paradoxically associated with improved cisplatin efficacy and patient survival. 
  
b Thought to be important for drugs in general, but not directly tested with platinum drugs. 
  
c Alter platinum cellular uptake and efficacy when added in vitro. 
  
d Effect not seen consistently across all studies, or opposite effect seen in some studies. 
  
e Demonstrated in clinical studies. 
   f Despite cells with low intracellular and extracellular pH having decreased platinum efflux and increased platinum uptake, binding and 
efficacy. 
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3.1. Resistance due to decreased blood flow and drug delivery 
 
As reviewed by Stewart [24], delivery of chemotherapeutic drugs and oxygen varies 
with blood flow. Hypoxia reduces efficacy of many agents, but has a little impact on 
platinum drugs [25]. With respect to drug delivery, tissue drug concentrations conform 
to either flow-limited models (varying with blood flow) [26] or to membrane-limited 
models (not proportional to flow) [27, 28]. In contrast to a flow-limited model for 
cisplatin, concentrations are as high in necrotic as in viable human tumors [29] and 
cisplatin concentrations in human autopsy tissues do not correlate with organ blood 
flow rates [30]. Human tumor cisplatin concentrations do vary with pulse and blood 
pressure, with metastatic site, and with tumor type [24, 29].  
Since blood flow autoregulation is defective in tumors, blood pressure fluctuations 
have greater impact on flow to tumors than to normal tissues [31], and agents that 
alter blood pressure may selectively alter tumor blood flow/drug delivery [31-33]. 
Decreased red blood cell deformability, high fibrinogen levels, etc. may reduce tumor 
blood flow by increasing blood viscosity [34, 35], while agents that reduce blood 
viscosity (e.g., pentoxifylline, mannitol or fibrinolytics [34, 36-38]) might increase 
tumor blood flow and drug delivery. While both blood flow [39] and drug diffusion 
through interstitium from vessel to tumor cell [40] may be impeded by the abnormally 
high tissue pressures in tumors, higher interstitial fluid pressures  may nevertheless be 
associated with increased platinum drugs efficacy and prolonged patient survival [41]. 
Overall, it is unknown to what extent tissue pressure and tumor blood flow affect 
platinum drugs activity clinically.  
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3.2. Resistance due to diminished accumulation 
 
Studies reported over the past 30 years have analyzed the ability of Pt-containing 
drugs to accumulate in cancer cell lines, measured the ability of new compounds to 
accumulate in resistant cells and have consistently demonstrated that accumulation of 
drug is a determinant of cellular resistance/sensitivity [42, 43]. Johnson et al. reported  
a strong correlation (r = 0.98) between cisplatin accumulation  and relative cisplatin 
resistance for a series of increasingly resistant lines derived from the BEL7404 human 
hepatoma cell line [44]. Koga et al. examined seven primary bladder cancer cell lines 
derived from untreated transitional cell cancer of the urinary bladder and found a 
positive correlation between cisplatin accumulation and sensitivity (r = -0.778) among 
the intrinsically resistant cell lines [45].  
It is important to note that the correlation between diminished accumulation of 
drug and increased cells resistance is not unique to cisplatin, and has been observed 
for the clinical analogs carboplatin [46] and oxaliplatin [47] and compounds in clinical 
trials as well [48, 49]. In addition, cross-resistance among platinum drugs was observed 
at an early stage of platinum drug research [50], and in some cases reflected reduced 
accumulation of these compounds (although there are exceptions) [46]. Stewart et al. 
examined platinum concentrations in human autopsy samples and demonstrated that 
patients whose tumors responded to Pt-containing therapies had higher tumor 
platinum concentrations than those that failed to response, seeming to indicate that 
platinum accumulation is an important factor for clinical efficacy [51]. 
It is presumed that accumulation of platinum drugs occurs by a variety of 
mechanisms, including passive diffusion and facilitated transport by multiple transport 
systems. To reduce drug accumulation to a significant extent, or to confer cross-
resistance to multiple cytotoxic Pt-containing drugs, cells must simultaneously 
inactivate more than one of these transport systems [19]. 
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3.2.1. Diminished accumulation caused by influence of extracellular 
environment 
 
3.2.1.1. Plasma and interstitium proteins 
Binding of platinum drugs to plasma and interstitium proteins may contribute to 
resistance. Platinum that is bound to protein is much less cytotoxic than is free [52, 
53], with substantially reduced uptake into cell [53] and tissues [54]. There is a general 
resemblance between the distribution patterns of cisplatin and carboplatin, although 
in vitro incubation with mouse plasma showed that number of interactions is higher 
for cisplatin [55]. The influence of protein-binding on oxaliplatin cytotoxicity has not 
been evaluated separately. 
Stewart reported [24] that cisplatin induced apoptosis is reduced in the presence of 
extracellular matrix proteins fibronectin, type IV collagen and laminin that may bind 
tumor cells [56]. Extracellular gamma-glutamyltransferase that may cleave glutathione 
to render thiol groups that bind and inactivate cisplatin and other electrophilic drugs 
also reduces apoptosis [57]. However, the impact of these factors in the clinic remains 
unknown. 
 
3.2.1.2. Extracellular pH 
Contrary of the tumor intracellular pH (that is neutral to alkaline), tumor 
extracellular pH is often acidic [58, 59]. It is because of anaerobic glycolysis that occurs 
in tumor cells. Lowering extracellular pH favors uptake of weak acids [58], markedly 
increases uptake of cisplatin and its DNA binding and also lowers intracellular pH [60]. 
In vivo, extracellular pH is lowered by intravenous glucose administration [61], while 
oral bicarbonate administration  raises it [62]. 
Other agents could also potentially have an impact on… [24]. For instance mannitol 
and NaCl, both used to reduce cisplatin nephrotoxicity, decrease cisplatin uptake and 
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cytotoxicity in vitro, as does KCl, while CaCl2 and CuCl2 may increase net cisplatin 
accumulation and cytotoxicity [63].  
In summary, there is substantial preclinical evidence suggesting that reduced 
extracellular and intracellular pH may be associated with platinum drugs uptake, 
binding and cytotoxicity, while increased extracellular pH may be associated with 
platinum drugs resistance. However, its clinical importance has not been adequately 
assessed yet [24].  
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3.2.2. Decreased drug uptake 
 
3.2.2.1. Passive diffusion 
It has long been presumed that cisplatin and carboplatin are taken up passively by 
the cell, as uptake is not saturable, nor it is inhibited by structural analogs [64]. Also 
oxaliplatin uptake was meant to be most likely passive, as a correlation between 
hydrophobicity and uptake has been shown [65]. Andrews demonstrated that Pt 
compounds could not lower accumulation by competitive inhibiton as would be 
expected if a unique active transporter were at play, whereas compounds that 
compromised membrane integrity increased accumulation [66].  
The relative amount of drug entering a cell by passive diffusion is dependent on the 
concentration of drug: at low drug concentrations, active transporter(s) may mediate 
the uptake of the majority of drug, but at high concentrations most uptake would be 
via passive diffusion. Collectively, there is evidence that drug can enter a cell by 
passive diffusion; however, given that resistant cells demonstrate only small changes 
(if any) in their membrane composition and biophysics, passive diffusion is not the key 
to decreased drug accumulation and the lowered accumulation must be due to other 
alterations (i.e. alterations of active mechanisms of uptake-see below) [19]. By reason 
that decreased drug uptake is thought to be dependent on alterations of active 
mechanisms, ability of drugs to enter cells by passive diffusion led to the design of 
lipophilic Pt-complexes that are capable of circumventing cisplatin resistance through 
increased accumulation in resistant cells, in a way independent of any active 
component of uptake [65, 67, 68]. 
  
3.2.2.2. Na+ ,K+ -ATPase and Na+ gradient 
Na+ ,K+ -ATPase primarily maintains the sodium gradient across the cell membrane 
(pumps sodium out and potassium into the cell). During the search for active uptake 
component Andrews et al. noted that preincubation with the Na+ ,K+ -ATPase-specific 
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inhibitor oubain reduced cisplatin accumulation in both the sensitive and the resistant 
cells by up to 50% [69, 70]. Short-term accumulation experiments showed that drug 
accumulation was immediately reduced on exposure, suggesting Na+ ,K+ -ATPase 
inhibition affects influx; replacement of sodium with choline in cell growth media 
reduced cisplatin uptake by a similar amount as oubain; and cisplatin uptake increases 
with extracellular sodium concentration, suggesting it is the sodium gradient 
dissipation rather than Na+ ,K+ -ATPase inhibition that lowers cisplatin uptake [69]. 
Interestingly, tissues subject to cisplatin toxicity, such as kidney and the inner ear, do 
express high levels of Na+ ,K+ -ATPase [69, 71]. Hall et al. reported that cisplatin is not a 
substrate for Na+ ,K+ -ATPase, and the inhibition  of Na+ ,K+ -ATPase by oubain reduces 
the Na+ gradient across the cell membrane that affects active/facilitated transport of 
cisplatin, although the specific transporters that rely on this sodium gradient have not 
been identified [19]. 
 
3.2.2.3. Gated channel Aquaporin 9 
Gately and Howell proposed that cisplatin accumulation could be facilitated via a 
gated channel, but cisplatin’s minimum cross-section (3.97 Å by 6.92 Å) is greater than 
that of biggest channel pores, with the possible exception of aquaporin 9, recently 
reported to have a pore size of approximately 7 Å by 12 Å [72]. Aquaporin 9 has been 
shown to permit the passage of neutral molecules, such as glycerol, urea, purines, and 
pyrimidines [73], and its expression correlates with As2O3 accumulation in myeloid and 
lymphoid leukemia lines [74].  
Although the ability for the aquaporins to transport Pt drugs has not been directly 
demonstrated, it is important to note that Pt-resistant lines have reduced expression 
of aquaporin 9, presenting a potential new Pt-drug transport family and new possibility 
that can contribute to Pt-drug resistance [19]. 
 
 
21 
 
3.2.2.4. Copper transporter CTR1 
Major inroads have been made recently in defining the role of transport of platinum 
drugs via copper transporter 1 (CTR1, SLC31A1) (Figure 3) into the cell as another 
determinant of drug sensitivity and resistance [75]. It has become clear that platinum 
drugs utilizes the copper transporters (and exporters), as well as other cation 
transporter [76]. CTR1 is an evolutionarily conserved copper influx transporter present 
in plant, yeast, and mammals, and is the main copper importer in mammalian cells. 
The human version, hCTR1, is expressed in all tissues and is a key player in the 
exquisite homeostatic regulation of intracellular copper levels [19, 77].   
Cisplatin, at plasma concentrations, not only prevents copper from being 
transported by CTR1 (cisplatin and copper are competitive inhibitors for the transport 
of the other molecule into the cell [75]) but also down-regulates protein expression of 
CTR1 in human  ovarian carcinoma cell lines [78]. Larson et al. demonstrated that 
exposure to cisplatin triggered the rapid degradation of mammalian CTR1, suggesting 
that its contribution to influx was likely to be on initial phase of drug entry. Loss of 
CTR1 decreased the initial binding of cisplatin to cells and reduced influx. Loss of CTR1 
also almost completely eliminated the initial influx of carboplatin and reduced the 
initial uptake of oxaliplatin [79]. Re-expression restored both cisplatin uptake and 
cytotoxicity [79]. It is not surprising that in comparing sensitive and resistant cell line 
pairs, the resistant small cell lung carcinoma (SCLC) line SR2 expresses less than half of 
CTR1 protein than its sensitive counterpart SCLC [80]. As expected SR2 cells take up 
much less cisplatin and carboplatin than SCLC cells [80]. Expression of transfected CTR1 
protein in SR2 cells results in an increase in the uptake rate of cisplatin [80].  
Although hCTR1 has been implicated in transport of cisplatin, carboplatin and 
oxaliplatin, it has been proposed to be important predominantly for the import of 
cisplatin and carboplatin into the cells [80, 81]. The results publicized by Holzer et al. 
[82] indicate that CTR1 regulates the cellular accumulation of all three drugs at 
concentrations attainable in humans but that at 5-fold higher concentrations, although 
accumulation of cisplatin and carboplatin is still CTR1-dependent, oxaliplatin 
accumulation becomes CTR1-independent, indicating that it is a substrate for another 
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cell-entry mechanism – a feature consistent with its different clinical spectrum of 
activity. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic diagram of hypothesized differences in copper (Cu) and platinum (Pt) drug 
vesicular sequestration, trafficking, and export pathways. Cu and the Pt drugs enter 
predominantly via hCTR1 and are sequestered by ATP7A/B into the trans-Golgi network (TGN) 
and vesicles of the secretory pathway. Cu triggers relocalization of vesicles that are then 
efficiently exported. The Pt drugs fail to trigger relocalization of vesicles into which they are 
sequestered by ATP7A, and the export of these vesicles appears to be limited (Adopted from 
[83]). 
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3.2.2.5. Organic cation transporters (OCTs) 
The organic cation transporters (OCTs) are the other key proteins involved in 
platinum drugs transporters [18]. The organic cation transporters (OCT) 1 (SCL22A1), 2 
(SLC22A2) and 3 (SLC22A3) are in the class of plasma membrane transporters 
belonging to the SLC22A family [84, 85]. The OCTs mediate intracellular uptake of a 
broad range of structurally diverse organic cations. Substrates of OCTs include 
endogenous compounds, such as choline, creatinine, and monoamine 
neurotransmitters, and variety of xenobiotics, and clinically used drugs, such as 
metformin, cimetidine, and amantadine [84]. In humans, OCT1 is primarily expressed 
in the liver [85-87] and less so in the intestine [88], whereas OCT2 is predominantly 
expressed in the proximal tubules of the kidney [84, 85]. OCT3 is expressed in many 
tissues, including placenta, heart, liver, and skeletal muscle [89, 90]. The expression of 
the OCTs has also been detected in several human cancer cell lines [91].  
The interactions of cisplatin with human OCTs has been investigated, and the 
results are discordant (Table 2) [92, 93]. In the recent study reported by Zhang et al. 
was observed that the influx transporters OCT1 and OCT2 play a critical role in the 
cellular uptake and consequently cytotoxicity of oxaliplatin. In contrast, the two 
transporters were relatively unimportant in mediating the uptake and cytotoxicity of 
cisplatin and carboplatin.  
Overexpression of OCT1 and, more strikingly, OCT2 in transfected cells not only 
increased the rate of cellular platinum drugs accumulation but also elevated the level 
of platinum-DNA adducts after oxaliplatin exposure [94]. Structure-activity relationship 
studies suggest that the 1, 2-diaminocyclohexane (DACH) moiety of oxaliplatin is an 
important pharmacophore for its interaction with the OCTs and that an organic on the 
nonleaving portion of the platinum complexes is essential. The greater affinity of 
oxaliplatin for these transporters, and their presence in colon cancer may be an 
explanation for its usefulness in this disease in contrast to other platinum drugs against 
which are colon cancer cells resistant [18, 95, 96]. 
In contrast to OCT1 and OCT2, overexpression of human OCT3 did not affect the 
cytotoxicity or resistance of any of the platinum drugs [94].
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Table 2 – Observations on cisplatin, carboplatin, and oxaliplatin substrate specificity for OCT1, 
OCT2, and OCT3 influx transporters (rat and human) (Adopted from [19]). 
 
 
 
 
 
 
   
Cisplatin 
OCT1 OCT2 OCT3 
Pan et al. [97] 
--- Yes --- 
Yonezawa et al. [98] 
No Yes --- 
Briz et al. [92] 
No No No 
Ciarimboli et al. [93] 
No Yes --- 
Yonezawa et al. [99] 
Yes(weak) Yes No 
Zhang et al. [94] 
Yes(weak) No No 
 
   
Carboplatin OCT1 OCT2 OCT3 
Ciarimboli et al. [93] 
--- No --- 
Yonezawa et al. [99] 
No No No 
Zhang et al. [94] 
Yes(weak) No No 
 
   
Oxaliplatin 
OCT1 OCT2 OCT3 
Ciarimboli et al. [93] 
--- No --- 
Yonezawa et al. [99] 
No Yes Yes(weak) 
Zhang et al. [94] 
Yes Yes No 
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3.2.3. Increased drug efflux 
 
3.2.3.1. Copper efflux transporters ATP7A and ATP7B 
Resistance may also be associated with increased platinum drugs efflux from cells 
[100] or from nucleus into cytoplasm [101]. The copper-transporting P-type adenosine 
triphosphatases ATP7A and ATP7B are implicated in platinum drugs efflux and 
resistance [83, 102-112] (Figure 3).  As reviewed by Rabik et al. [9], ATP7A/B are 
primarily responsible for the export of copper from the cell.  Under normal (Cu replete) 
conditions, ATP7A/ATP7B reside in the trans-Golgi network, where they receive Cu 
from the chaperone Atox1 and translocate it to the luminal side for incorporation into 
enzymes. When excess Cu exists in the cell, ATP7A/B are trafficked to the cell surface 
to directly efflux Cu from the cell [77].  
ATP7B was first proposed to be involved in cisplatin resistance when Komatsu et al. 
overexpressed this transporter in human epidermoid carcinoma cells and observed 
that these cells gained resistance to cisplatin as a result of ATP7B overexpression [113]. 
Cisplatin accumulation in ATP7B transfected cells was only 60% of that observed in 
cells transfected with empty vector. It was due to ability of ATP7B to sequester 
cisplatin into vesicles and transport it similar to copper out of the cell. Additionally, 
eighty-two primary ovarian carcinomas were profiled for expression of several known 
resistance genes – including ATP7B, MDR1, MRP1, MRP2, LRP, and BCRP [114]. With 
the exception of ATP7B, none were indicators for resistance of ovarian cancer to 
cisplatin.  
Patients whose carcinomas express high levels of ATP7B have a significantly poorer 
prognosis than patients with tumors that express low level of ATP7B [103]. ATP7B 
overexpression is associated with poor outcome in cisplatin-treated patients with 
ovarian carcinoma [103], esophageal cancer [108], squamous cell cancer of the head 
and neck [110] or human endometrial carcinoma [105], human solid carcinoma [112], 
human non-small cell lung cancer [109], human hepatocellular carcinoma [106]. 
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In accordance with Samimi et al. [83] ATP7A is able to sequester into vesicles not 
only cisplatin, but also both carboplatin and oxaliplatin. Increased expression of ATP7A 
in the 2008 cell line of ovarian carcinoma leads to increased resistance to all three of 
the clinically available Pt drugs; interestingly, overexpression leads to increased 
sequestration of platinum drugs and not to decreased total accumulation [83]. This 
seems to suggest that simple overexpression of ATP7A alone may be sufficient to 
compartmentalize and deactivate Pt, but not be enough to lower accumulation. ATP7A 
is not relocalized to the plasma membrane for Pt efflux as it is for Cu efflux, suggesting 
the Cu sensing domain associated with trafficking cannot sense Pt [115].  
In contrast with these outcomes, Rabik et al. presented data demonstrating that the 
expression of both ATP7A and ATP7B provide increased cellular resistance to cisplatin, 
while cells become hypersensitive to oxaliplatin [81]. This is in agreement with 
outcomes presented by Samimi et al. [116] and also by Plasencia et al. [117] who 
reported that oxaliplatin resistant colon cancer cells exhibited low basal expression 
levels of ATP7A (and ATP7B) compared to parent, non-resistant, cells. 
Overall, the role of ATP7A and ATP7B transporters in platinum drug sensitivity has 
not been completely elucidated. Some results contradict each other. The answer to 
these discrepancies could be found in tissue specificity. The potential tissue specificity 
should be analyzed through both overexpression and knockdown experiments in 
tumor cell lines to determinate the role of these transporters in clinical resistance and 
sensitivity to platinum drugs. In some tumor types, these transporters may be vital in 
providing resistance to platinum drugs, and this can be targeted in developing new 
therapies to modulate platinum drugs treatment. 
 
3.2.3.2. Drug efflux transporters 
The chelation of Pt drugs by glutathione is generally accepted to be a deactivation 
pathway (see below). Once the Pt drug is chelated by glutathione, the glutathione-Pt 
complex is effluxed from the cell in an ATP-dependent way by a transporter family 
termed MRP (ABCC) drug efflux transporters [118]. MRP drug efflux transporters are 
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ATP-dependent organic anion transporters. The first identified member of the family 
was the multidrug resistance-associated protein 1 (MRP1, ABCC1), a glycoprotein 
capable of effluxing a range of glutathione-conjugated molecules, and a member of the 
ABC (ATP-binding cassette) family of drug efflux transporters [119]. Seven more MRP1 
homologues have subsequently been indentified (MRP2-MRP8) but their importance in 
platinum drugs resistance remains unclear. Glutathione-conjugated Pt is already 
deactivated, so efflux by the MRP transporters is not necessarily a part of the 
accumulation-resistance phenotype; however, there is evidence in specific cases that 
their expression is associated with clinical resistance to cisplatin, but more work needs 
to be done [19]. 
Other drug efflux transporters that play important role in regulation of intracellular 
drug concentrations and thereby determining cell sensitivity to chemotherapeutic 
agents are ATP-binding cassette (ABC) drug efflux transporters ABCB1 (P-glycoprotein, 
MDR1) and ABCG2 (Breast cancer resistance protein, BCRP).  
As discussed in the work of Ceckova et al. [120] the influence of ABCG2 on cisplatin 
resistance is unclear and there are remarkable discrepancies in current literature 
evaluating its importance. Several studies demonstrated no correlation between 
expression of ABCG2 and cisplatin resistance [121, 122]. However, dramatic up-
regulation of mRNA expression of ABCG2 has been recently reported in oxaliplatin-
resistant colorectal cancer cell line [123] and a correlation between ABCG2 positivity of 
tumor cells and low response rate to platinum-based chemotherapy has been 
described in patients with advanced non-small cell lung cancer (NSCLC), suggesting the 
ABCG2 efflux transporter to be responsible for drug resistance in patients with NSCLC 
[124]. 
ABCB1 seems to be unimportant in platinum drugs resistance as several studies 
demonstrated no correlation between its expression and cisplatin resistance [114, 
125].  
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3.3. Drug detoxification 
 
3.3.1. Glutathione and Glutathione-S-transferase 
In the cytoplasm, platinum drugs become aquated, which then enables them to 
react with thiol-containing molecules, including glutathione (GSH) and 
metallothioneins. Increased concentrations of these compounds are known to induce 
resistance against cisplatin [126-129]. However, few studies have described the role of 
these enzymes in oxaliplatin detoxification [117].Glutathione itself acts as an 
antioxidant of the cell, it helps to maintain the redox environment while maintaining 
reduced sulfhydryl groups. The resistance induced by GSH may be caused by 
binding/inactivating cisplatin, enhancing DNA repair, or reducing cisplatin-induced 
oxidative stress [126]. 
Rabik et al. [9] reviewed that in bladder carcinoma cell lines that are known to be 
resistant to cisplatin, exposure to buthiomine sulfoximine (BSO), which significantly 
depletes cellular glutathione concentration, resulted in a significant enhancement in 
cisplatin cytotoxicity [129]. Additionally, the NSAID (non-steroidal anti-inflamatory 
drug) indomethacin significantly decreases cellular concentrations of GSH and 
sensitizes bladder carcinoma cells to cisplatin treatment [129]. However, neither of 
these treatments sensitizes these cells to the level of their parent sensitive strain, 
indicating either that glutathione levels are only one component of cisplatin resistance 
[129], or that the NSAID may have other effects in the cell that prevent complete 
sensitization [9]. 
Glutathione-S-transferase (GST), particularly GST-π [130-136] or specific GST-π 
polymorphisms [136], may augment resistance by catalyzing GSH-drug binding. Colon, 
lung adenocarcinoma, and glioblastoma tumor cell lines [137], and ovarian [135, 138, 
139] and head and neck clinical samples [140] do exhibit a correlation between high 
GST-π levels and cisplatin resistance. However, in other studies of ovarian, cervical, 
and lung carcinoma, no relationship was evident [141-144]. Another study has shown 
that ovarian cancers with high expression of GST-π typically have lower survival and 
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less favorable response to cisplatin. Much of the GSH/GST data is conflicting, leading to 
question about its importance. While it may have some role in certain types of cancers, 
it does not appear to be a global indicator of cisplatin resistance [9].  
 
3.3.2. Metallothioneins 
Metallothioneins (MT) are very low molecular weight proteins comprised of several 
cysteine and aromatic amino acid residues. They are thought to be involved in 
controlling levels of copper and zinc, as well as protecting cells from oxidative stress 
and toxicities associated with heavy metals, including copper, cadmium, and zinc [145, 
146]. Elevated levels of metallothionein II have been described in cisplatin-resistant 
cell lines. Human bladder cancer xenografts [146] and esophageal [147] and 
transitional cell primary carcinomas [148] that express high levels of MT exhibit less of 
a clinical response to cisplatin. In head and neck cancers, cisplatin induces 
metallothionein expression [149], while in germ cell and testicular tumors, no 
relationship  between MT and cisplatin was observed [150]. The association of MT 
levels with cisplatin resistance may be tissue specific and may play a minor role 
depending on the cellular environment [9].  
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3.4. Platinum drugs and DNA  
 
3.4.1. Drug binding and DNA lesions 
Upon entering a cell, all platinum drugs become aquated, losing chloride or oxalate 
ions, and gaining two water molecules. This positively charged molecule is then able to 
interact with nucleophilic molecules within the cell, including DNA, RNA, and proteins 
[9], although it is  generally agreed that DNA is the preferential and cytotoxic target for 
cisplatin and other platinum drugs [151]. Platinum drugs cytotoxicity and DNA binding 
are highest with cell exposure during G1 and lowest during G2/M [152]. Reducing 
histone methylation relaxes condensed chromatin, increases cisplatin access to DNA, 
increases DNA-platinum adduct formation, and augments platinum drugs efficacy 
[153]. Rabik et al. reviewed that when binding to DNA, platinum drugs favor the N7 
atoms of the imidazole rings of guanosine and adenosine. Three different types of 
lesions can form on purine bases of DNA: monoadducts, intrastrand crosslinks, and 
interstrand crosslinks (Figure 4). Monoadducts are first formed as one molecule of 
water is lost from aquated platinum drugs; however, greater than 90% of 
monoadducts then react to form crosslinks. Almost all of these crosslinks are 
intrastrand, with the majority being 1,2-d(GpG) crosslinks (for cisplatin 60-65%) and 
1,2-d(ApG) crosslinks (for cisplatin 20-25%). Oxaliplatin forms fewer crosslinks than 
cisplatin at equimolar concentrations; however, it is equally as potent at these 
concentrations [154, 155] and is able to induce similar numbers of single-strand and 
double-strand breaks on DNA [156].  
All crosslinks result in contortion of DNA [157]. Cisplatin and carboplatin intrastrand 
crosslinks bend the double helix by 32-35° toward the major groove, whereas 
oxaliplatin treatment bends the helix even further [65]. Both 1,2-d(GpG) and 1,2-
d(ApG) intrastrand crosslinks unwind DNA by 13°, while the 1,3-d(GpXpG) intrastrand 
lesion unwinds DNA by 34°. Interstrand lesions induce even more steric changes in 
DNA, with extrusion of the cytosines at the crosslinked d(GpC)d(GpC) sites, bending of 
the double helix toward the minor groove by 20-40°, and extensive DNA unwinding of 
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up to 80°. Oxaliplatin adducts are bulkier and more hydrophobic than those formed 
from cisplatin or carboplatin, leading to different effects in the cell [17].  
 
 
 
 
 
 
 
 
 
Figure 4. Platinum drugs adducts on DNA. Platinum drugs are able to react with DNA to form 
monoadducts, intrastrand crosslinks (1,2-d(GpG), 1,2-d(ApG), 1,3-d(GpXpGp)), interstrand 
crosslinks (G-G), and DNA–protein crosslinks (Adopted from [9]). 
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There are different theories as to which lesion is responsible for cytotoxicity. Some 
believe that the interstrand crosslink is cytotoxic because of the level of distortion in 
the DNA; however, most believe that the predominant 1,2-intrastrand crosslinks are 
the cytotoxic lesion. It is because of comparisons with the biologically inactive trans 
isomer of cisplatin, trans-diamminedichlorplatinum (II) (trans-DDP). Due to steric 
reasons, trans-DDP is unable to form 1,2-intrastrand adducts between two adjacent 
purines in the same DNA strand, so trans-DDP mainly forms 1,3-intrastrand and 
interstrand crosslinks [158]. It is generally accepted that 1,2-intrastrand DNA adduct is 
responsible for the anticancer activity of cisplatin (although the possible importance of 
other adducts should not be ruled out).  
This assumption is supported by the discovery that some High mobility group 
(HMG) proteins specifically recognize this type of DNA adduct and therefore may 
regulate the processing of 1,2-d(GpG) intrastrand crosslinks formed by cisplatin [159]. 
Their presence is thought to be crucial also for sensitivity to carboplatin. The binding of 
HMG-1 to cisplatin helps in preventing replicative bypass (see below) [160] and HMG 
proteins such as SRY, UBF, and LEF-1 have been shown to block nucleotide excision 
repair (NER; see below) components from repairing the lesion via a “shielding 
mechanism” [161]. The cisplatin-DNA-HMG-1 ternary complex is also able to block 
transcription factors, thus preventing both transcription and replication. This block in 
cellular processes may be responsible for sending out DNA damage signals that result 
in initiation of apoptosis [126]. HMG has a much lower affinity for oxaliplatin crosslinks 
on DNA than it does for cisplatin or carboplatin adducts [160]. The molecular geometry 
of the oxaliplatin adduct , with a narrower major groove and correspondingly wider 
minor groove, is thought to be responsible for this observation [9]. 
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3.4.2. Repair of DNA lesions 
  
3.4.2.1. Nucleotide excision repair  
The ability of cells to repair DNA damage appears to be a critical determinant of 
resistance or sensitivity to platinum drugs. Nucleotide excision repair (NER) pathway is 
one of the major pathways involved in repair of DNA damage caused by platinum 
drugs. NER includes the recognition of DNA damage and demarcation of the specific 
area affected, followed by the formation of a complex to unwind the damaged portion 
and excise it. Finally, the excised area is resynthesized and ligated to maintain the DNA 
molecule [162] (Figure 5). 
 While NER recognizes all three types of intrastrand crosslinks (1,2-d(ApG), 1,2-
d(GpG), and 1,3-d(GpNpG)), the 1,2 intrastrand crosslinks are repaired less efficiently 
than the 1,3 intrastrand crosslinks, supporting the hypothesis that the 1,2 intrastrand 
crosslinks are the cytotoxic lesion [163, 164]. High levels of specific proteins of this 
pathway are expressed in cisplatin resistant cells [165, 166]. Rabik et al. reviewed that 
in ovarian cancer, XPA and ERCC1 (excision repair-complementation group)/XPF 
(xeroderma pigmentosum complementation group F) were shown to have increased 
expression in tumors of patients resistant to platinum drugs treatment [167, 168]. In 
primary ovarian tumors, levels of XPB transcripts were significantly higher in tumors 
resistant to cisplatin than in tumor samples from patients who responded well to 
platinum drugs treatment [169]. Similarly, gastric cancer showed a correlation 
between cisplatin resistance and ERCC1/XPF mRNA levels [170]. In addition, cell lines 
that developed resistance in vitro after exposure to cisplatin chemotherapy were 
found to have increased expression of ERCC1 [171]. 
Koberle reported that testis tumor cell lines, generally very responsive to cisplatin, 
has low levels of XPA and ERCC1/XPF. This is sufficient to explain their poor ability to 
remove cisplatin adducts from DNA and is providing further correlative evidence for 
the importance of NER in cisplatin resistance [172, 173]. Oxaliplatin treatment also 
induces the expression of NER genes and the rate and kinetics of NER are similar to 
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cisplatin [174]. In HT29 colon cancer cells, expression of ERCC1 and XPD was 
significantly higher in cells treated with oxaliplatin compared to untreated control cells 
[117] and also the median overall survival was significantly longer in patients without 
ERCC1 expression [175]. 
NER may be inhibited by the presence of nucleosomes along the DNA. Previous 
studies have indicated that the presence of nucleosome on DNA is able to inhibit NER 
in cells treated with DNA damaging agents, including cisplatin [176, 177]. Comparison 
of the extent of repair by mammalian cell extracts of free and nucleosomal DNA 
containing the same platinum-DNA adduct reveals that the nucleosome significantly 
inhibits nucleotide excision repair. With the d(GpTpG) DNA substrate, the nucleosome 
inhibits excision to about 10% of the level observed with free DNA, whereas with the 
less efficient d(GpG) DNA substrate the nucleosome inhibited excision to about 30% of 
the level observed with free DNA [177]. Nucleosome induced NER inhibition may be 
overcome by the activity of the SWI/SNF chromatin remodeling complex, which is 
activated upon damage recognition by the NER factors XPA and SPC [178]. Although 
SWI/SNF was not shown to be crucial for platinum drugs resistance/sensitivity, 
inhibition of this pathway may lead to a targeted therapy for sensitization of tumors to 
cisplatin and other DNA damaging agents.  
  
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A, NER-
nucleotide excision repair 
begins when a DNA adduct 
is formed and causes a 
change in the shape of the 
DNA helix. B, damaged 
DNA binding factor binds 
to preincision complex and 
this protein complex 
localizes to the damaged 
area of DNA. C, the DNA 
helix is unwound and the 
damaged portion is 
excised by ERCC1/XPF. D, 
DNA polymerase then 
resynthesizes the absent 
portion of DNA. E, when 
NER-nucleotide excision 
repair is complete, the 
DNA is repaired and 
resumes its normal helical 
shape. In the setting of 
ERCC1deficiency,the DNA 
cannot be repaired, and 
the altered DNA is unable 
to replicate, or perform its 
normal function, leading 
to cell death (Adopted 
from [162].  
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3.4.2.2. Mismatch repair 
As reviewed by Topping, the mismatch repair (MMR) system of proteins plays roles 
in diverse cellular processes, perhaps most notably in preserving genomic integrity by 
recognizing and facilitating the repair of post-DNA replication base pairing errors. 
Recognition of these errors and recruitment of repair machinery is performed by the 
MutSα complex (consisting of the MMR proteins MSH2 and MSH6) or MutSβ complex 
(consisting of MSH2 and MSH3) [179] (Figure 6). When MMR is deficient, unrepaired 
areas of DNA accumulate, resulting in microsatellite instability (MSI) [180]. This 
accumulation occurs when unrepaired base pair mismatches are replicated during DNA 
synthesis [162]. 
In addition to their role in DNA repair, MMR proteins also play a role in cytotoxicity 
induced by specific types of DNA damaging chemotherapeutic drugs, such as cisplatin. 
MutSα recognizes multiple types of DNA damage, including 1,2-intrastrand cisplatin 
adducts. Cisplatin adducts interfere with normal MMR activity, prevent a repair from 
being completed, and therefore treatment with cisplatin results in MMR protein-
dependent cell cycle arrest and cell death [179, 181-184]. MMR proteins thus serve to 
detect the DNA damage caused by platinum drugs and generate an injury signal that 
eventually contributes to the triggering of the apoptic reaction that destroys the cell 
[4]. MMR mediates cisplatin and carboplatin induced apoptosis [185-187] but there is 
no difference in sensitivity between MMR-proficient and MMR-deficient cells for 
oxaliplatin [4].  
The MMR protein-dependent cytotoxic response to cisplatin is largely unknown. 
Previous studies reported that only the p53-related transactivator protein p73 and the 
c-Abl kinase were clearly implicated as potential mediators of cisplatin/MMR protein-
dependent cell death in human cells [188, 189]. However, recent studies show that 
cisplatin induced MMR protein-dependent cytotoxic response is independent of p53 
signaling and demonstrate a MMR protein-dependent pro-death signaling pathway in 
cells treated with cisplatin [179].  
Pro-death members of the Bcl-2 family, such as Bax and Bak, target the outer 
mitochondrial membrane and cause the cytosolic release of pro-death factors residing 
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within the mitochondria of unstressed cell [190]. Predominant among these factors is 
cytochrome c, whose cytoplasmatic localization results in the formation of caspase-
activating platform (caspase-Cysteine Aspartate Specific proteinASE) known as the 
apoptosome [191]. This complex includes the adaptor protein Apaf-1, and when 
formed the apoptosome promotes the cleavage and activation of caspase-9 [192, 193]. 
Once activated, this apical caspase proceeds to cleave and activate caspase-3, the 
predominant effector protease of apoptosis [179]. Cleaved caspase-3 can cleave a 
number of substrates, including poly(ADP-ribose) polymerase (PARP). 
MMR seems to be important for cisplatin and carboplatin cytotoxicity. It is 
connected with triggering of apoptosis and therefore MMR deficiency or inhibition of 
apoptosis (see below) can cause cisplatin and carboplatin resistance; however, 
deficiency of MMR does not affect cytotoxicity of oxaliplatin. This is particularly 
important in the usage of oxaliplatin to treat mismatch repair deficient tumors (e.g. 
colorectal cancer) that are resistant to cisplatin and carboplatin.  
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Figure 6. A, MMR occurs when the Mut protein recognizes a mismatch or insertion/deletion 
loop. B, theMut protein orders the assembly of a protein complex which localizes to the 
affected area on the DNA molecule and excises it. C, DNA polymerase then resynthesizes the 
missing portion of DNA. D, accumulation of insertion deletion loops on a strand of DNA in the 
petting of MMR deficiency (Adopted from [162]).  
39 
 
3.4.2.3. Homologous recombination 
Homologous recombination has been proposed to play a role in repairing double 
strand brakes resulting from cisplatin-induced interstrand DNA adducts [194]. This can 
be caused by NER components XPF and ERCC1 [195, 196] and by proteins BRCA1 and 
BRCA2 (breast cancer type 1,2 susceptibility proteins). As reviewed by Powell and 
Kachnic BRCA2 has been shown to play a direct role in the repair of DNA by 
homologous recombination, by interacting with the Rad51 protein and facilitating the 
formation of Rad51 aggregates at the site of DNA damage. In the absence of BRCA2, 
the cell is more dependent on residual repair via Rad52, which makes Rad52 a target 
for therapy in BRCA-deficient tumors. BRCA1 plays a role in sensing DNA damage and 
replication stress and mediating the signaling responses [197].  
Powell and Kachnic demonstrated that the defect in homologous recombination 
changes the drug sensitivity profile, rendering the BRCA-deficient breast cancers 
sensitive to cisplatin and other drugs that produce complex double-stranded lesions in 
DNA [197]. Additionally, Tassone et al. demonstrated increased sensitivity of human 
breast cancer xenografts to platinum drugs in BRCA1-defective cells [198]. These 
results suggest the influence of BRCA1 and BRCA2 on resistance to platinum drugs and 
good prognosis of patients with BRCA-deficient tumors. 
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3.4.3. Adduct tolerance 
 
3.4.3.1. Replicative bypass  
According to Rabik and Dolan [9], platinum drugs tolerance can be achieved without 
the need for DNA repair. In order for platinated DNA to be replicated and tolerance to 
form, DNA polymerase must skip the platinum adduct, which is most commonly an 
intrastrand lesion. The classic DNA replication polymerases – α, θ, and ε – cannot  
bypass the lesion; however, several polymerases have been shown to bypass 
intrastrand crosslinks by translesion synthesis – namely, β, η, ζ, and τ [199-203].  
Dong et al. [204] examined expression of pol-β in patients with esophageal cancer, 
and found that pol-β expression in tumor tissue was higher than in the corresponding 
normal tissue. Iwatuski et al. [205] in recent study demonstrated that pol-β 
suppression increases cisplatin sensitivity, but interestingly, does not affect oxaliplatin-
mediated cytotoxicity. This is consistent with previous studies that showed 
dependence of cisplatin resistance on pol-β overexpression [206, 207]. 
Pol-ζ has been shown in MMR deficient cells to play a role in DNA tolerance and 
bypass of lesions [208]. Recent experiments with pol-η null and expressing variant of 
human fibroblast cells have shown significance of pol-η in platinum drugs resistance 
and have demonstrated that the absence of pol-η results in a statistically significant 
enhancement in cisplatin, carboplatin as well as in oxaliplatin sensitivity [209]. 
However, bypassing oxaliplatin adducts is caused in particular by pol-ζ and pol-γ 
without evident influence of pol-β which can be an additional clue for the difference 
between mechanisms of action of cisplatin, carboplatin and oxaliplatin [160].  
 
3.4.3.2. Reduced apoptic response 
Several genes regulating DNA damage, apoptosis and survival signaling may 
contribute to resistance [210]. Platinum drugs may induce apoptosis through the Fas-
receptor/Fas-ligand signaling complex (with activation of caspase-8, then caspase-3, -6, 
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-7), by mitochondrial cytochrome-c release [159], or by defective apoptic pathway (i.e., 
p53) [211].  
As reviewed by Stewart [24], cells with p53 deletions or mutations are often 
resistant to cisplatin [212, 213]. Cisplatin resistance has been associated with p53 
mutation in vitro in ovarian carcinoma [214], head and neck squamous cell carcinoma 
[215], and clinically in germ cell tumors [216] and advanced laryngeal carcinoma [217].  
Caspases-3, -8 and -9 are important in cisplatin-induced apoptosis [126]. A cisplatin 
resistant lines have global downregulation of caspase and Bax expression, but 
increased Bcl-2 [218]. Decreased Fas expression or pathway activation after cisplatin 
may lead to inhibition  of activation of caspase-3 and -8 [126], and was associated with 
resistance in germ cell tumors [219] and ovarian carcinoma cells [220]. Loss of caspase-
8 pathway was associated with resistance in a human laryngeal squamous cell 
carcinoma cell lines [221]. Decreased cisplatin caspase-9 activation was noted in cells 
with normal mitochondrial cytochrome-c release and normal Bcl-2 and Bcl-xL 
expression [222]. Cisplatin-resistant cells have also been reported with abnormal 
mitochondrial membrane potential, intracellular distribution, or structure, and with 
up-regulation of cytochrome-c in the mitochondria in response to cisplatin rather than 
release into the cytoplasm [223].  
 
3.4.3.3. Apoptosis inhibitors  
Apoptosis can be inhibited by overexpression of X-linked inhibitor of apoptosis 
proteins (Xiap), an intracellular anti-apoptic proteins, that plays a key role in cell 
survival by modulating death signaling pathways, including modulation of the PI3-
K/Akt pathway [224]. Overexpression of Xiap and other anti-apoptic proteins (incl. IAP-
2 (inhibitor of apoptosis protein) and survivin) correlated with cisplatin resistance in 
cisplatin-resistant prostate cancer cells [225]. Similar, Xiap down-regulation increased 
cisplatin sensitivity, caspase-3 activity and apoptosis in resistant ovarian carcinoma 
[226] and prostate cancer cells [227]. Transfection with hRFI (ring finger domain highly 
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homologous to XIAP) induced cisplatin resistance and inactivation of caspase-3 in 
colorectal cancer cells (where it is naturally preferentially expressed) [228]. 
Overexpression of Bcl-2 and Bcl-xL genes (with marked downregulation of caspase-3 
expression [229]) may contribute to apoptic inhibition and the development of 
cisplatin-resistance in human ovarian cancer [230, 231]. Bcl-xL is also up-regulated in 
cells adapted to hypoxic stress and contributes to their resistance to cisplatin 
treatment [232]. In addition, nitric oxide (NO) induces Bcl-2 S-nitrosylation, inhibits its 
ubiquitination and upregulates Bcl-2 expression. NO synthase activity and NO 
production correlate with resistance in NSCLC cells [233].  
Overexpression of ribosomal proteins (RP) S13 and RPL23 can promote cisplatin 
resistance in gastric cancer cells by suppressing drug-induced apoptosis (through 
increased Bcl-2 expression and the Bcl-2/Bax ratio) and increasing GST activity and 
intracellular GSH content [234]. Resistant cells may also exhibit overexpression of the 
Bcl-2 related protein Bfl-1/A1, mediated by nuclear factor-kappaB (NF-kappaB) [235].  
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3.5. Newer molecular factors linked to platinum drugs resistance 
 
3.5.1.  Cyclooxygenase-2 (COX-2) 
As reviewed by Stewart [24], in preclinical studies, cisplatin treatment augmented 
tumor cell Cyclooxygenase-2 (COX-2) expression [236] and cisplatin resistance was 
induced by COX-2 overexpression. Clinically, high COX-2 expression was associated  
with reduced platinum-based  therapy efficacy in esophageal [237, 238], bladder [239], 
cervical [240], and ovarian [241] cancers. The fact that a link is seen between therapy 
efficacy and COX-2 expression clinically makes the assessment of COX-2 inhibitors a 
particularly interesting focus for further research. 
 
3.5.2. Heat shock proteins 
Heat shock protein (HSP) HSP27 overexpression or gene transfection [242, 243] as 
well as overexpression of HSP-90β [244] and HSP70 also may augment cisplatin 
resistance, and cisplatin treatment increases HSP70 expression in vitro [245]. HSP 
inhibitors are currently undergoing clinical trials, but little is known regarding the role 
of HSP in clinical resistance, and it remains unknown whether HSP inhibitors will prove 
useful. 
 
3.5.3. cAMP-phosphodiesterase-2 
The gene PDE2, encoding cAMP-phosphodiesterase-2, may induce resistance by 
increasing tolerance of cisplatin-induced DNA lesions [246]. 
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3.5.4. Cell cycle related factors 
S-phase-kinase-associated-protein-2 (SKP2) controls stability of cell cycle related 
proteins. SKP2 overexpression reduced expression of p27Kip1, cyclin e, and p21Cip1, 
increased S-phase cells, and increased cisplatin resistance, while SKP2 downregulation 
increased sensitivity in vitro [247]. Cyclin D1 overexpression augmented pancreatic 
cancer cell chemoresistance both by promoting cell proliferation and by inhibiting 
drug-induced apoptosis in association with upregulation of NF-kappaB activity [248].  
 
3.5.5. NF-kappaB 
Up-regulation of expression of antiapoptic factors by NF-kappaB may antagonize 
cisplatin-induced apoptosis [249], and cisplatin significantly increases NF-kappaB DNA 
binding activity [250, 251]. NF-kappaB inhibitors augment platinum drugs activity 
against  some cancer cell lines [251-254] and tumor xenograft models [250], but not 
against normal cells [251, 252] nor against some other cancer cell lines [251, 254]. 
 
3.5.6. Chromosomal alterations 
Platinum drugs-resistant cells may have several chromosomal abnormalities [255, 
256]. Telomere length, telomerase activity, and telomerase mRNA expression were 
reduced in cisplatin resistant ovarian carcinoma cell lines [257], and ovarian 
carcinomas with a loss of microsatelite D6S1581 were cisplatin-resistant [258]. 
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4. Conclusion 
  
46 
 
This thesis evaluated possible ways of development of platinum drugs resistance. A 
variety of mechanisms has been described; however, none of them seems to be crucial 
in all resistant tumors. Moreover, none of them seems to be essential for all platinum 
drugs. The mechanisms by which cells acquire resistance to platinum drugs are mainly: 
(i) diminished accumulation of platinum complexes, (ii) increased detoxification of drug 
by the thiols glutathione and metallothionein, and (iii) improved repair of nuclear 
lesions and tolerance to them, leading to a reduction in apoptosis.  
Platinum drugs probably enter cells by a number of influx transporters (especially 
by gated channel Aquaporine 9, Copper transporter CTR1 and Organic cation 
transporters OCT1 and OCT2) along with passive diffusion, and they can be extruded 
via the Cu efflux systems (including copper efflux transporters ATP7A and ATP7B) or 
possibly via drug efflux transporters (ABCG2). It is clear from a review of the literature 
that disagreement exists about the relative importance of each of these transport 
pathways to platinum drugs accumulation. Studies of sensitive and resistant cell lines 
have not been able to identify a single transporter whose decreased presence on the 
plasma membrane significantly contributes to a reduction in accumulation of platinum 
drugs. It seems that to reduce drug accumulation to a significant extent, or to confer 
cross-resistance to multiple cytotoxic platinum drugs, cells must simultaneously 
inactivate more than one of these transport systems. 
Cell antioxidants glutathione and metallothionein also seem to play a role in 
platinum drugs resistance. They contain thiol molecules that can bind/inactivate 
platinum drugs and they can also contribute to enhancement of DNA repair and 
reduction of cisplatin-induced oxidative stress. However, much of the data is 
conflicting leading to question about their importance. They may have some role in 
certain types of cancers, but they do not appear to be a global indicator of cisplatin 
resistance. 
As the cytotoxic effects of platinum drugs are caused by binding to DNA and 
formation of intrastrand and interstrand crosslinks, the most important mechanisms 
that contribute to platinum drugs resistance is improved repair of nuclear lesions and 
enhanced tolerance to DNA adducts. Nucleotide excision repair pathway, one of the 
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major pathways involved in repair of DNA damage, recognizes DNA damage, forms a 
complex that unwinds the damage portion and excises it. Finally, it re-synthesizes and 
ligates the excised area to maintain the DNA molecule. The importance of this pathway 
was approved by overexpression of specific proteins of this pathway in cells of many 
Pt-resistant tumors (e.g. ovarian, gastric, testis cancer, etc.). Mismatch repair system 
of proteins, another determinant of platinum drugs sensitivity/resistance, plays a role 
in preserving genomic integrity by facilitating the repair of post-DNA replication base 
pairing errors. Platinum drugs prevent a repair from being completed and therefore 
treatment with platinum drugs results in MMR dependent triggering of apoptosis. 
Another one DNA repair mechanism is the homologous recombination. It is proposed 
to play a role in repairing double strand brakes resulting from platinum drugs-induced 
interstrand DNA adducts. 
Enhanced DNA adduct tolerance and reduction in apoptosis can appear if DNA 
polymerases skip the platinum adduct by translesion synthesis. This bypass can be 
caused by polymerase β, η, ζ, τ and is in common called Replicative bypass. Other 
cause for adduct tolerance is reduced apoptic response that can appear due to 
inhibition of pro-apoptic factors (caspase-3, -8, Fas, …) or due to overexpression of 
apoptosis inhibitors (Xiap, Bcl-2, Bcl-xL). 
There are also several new molecular factors that have been linked to platinum 
drugs resistance (e.g. COX-2, HSP, cAMP-phosphodiesterase-2, NF-kappaB and other). 
With only a few exceptions, the effect on platinum drugs efficacy has been assessed 
only in vitro to date, with little information on their impact on resistance in xenograft 
models or in clinical use. 
Overall, this thesis summarized most of yet known mechanisms that contribute to 
platinum drugs resistance. Some of them seem to be crucial in determining platinum 
drugs efficacy, but importance of most of them remains unclear. Therefore more work 
needs to be done to determine to which extent these mechanisms influence resistance 
to platinum drugs and influence their efficacy in the pharmacotherapy.  
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5. Abstract 
 
Although the first platinum drug cisplatin was initially described in 1845, its 
biological activity was discovered more than 100 years later. Since then are cisplatin 
and its clinically used analogues carboplatin and oxaliplatin in widespread use for the 
treatment of variety of human cancers, including ovarian, cervical, head and neck 
tumors, non-small cell lung, breast, colon, gastric and renal cell carcinoma, sarcoma 
and relapsed lymphoma. However, the treatment is often accompanied by severe side 
effects of which nephrotoxicity, peripheral neurotoxicity and myelosuppression are the 
most serious. Another important obstacle in their clinical use is drug resistance. This 
thesis evaluates possible mechanisms of the development of platinum drugs 
resistance. There is a variety of them and they include (i) diminished accumulation of 
platinum drugs affected by influx transporters (Aquaporin 9, CTR1, OCT1, OCT2) and by 
efflux transporters (ATP7A, ATP7B,ABCG2); (ii) increased detoxification of drug by 
thiols glutathione and metallothionein; (iii) improved repair of nuclear lesions affected 
by NER, MMR, Homologous recombination, and enhanced tolerance to nuclear lesions 
caused by Replicative bypass, inhibition of pro-apoptic factors (including caspase-3, -8, 
Fas and other), or by overexpression of apoptosis inhibitors (Xiap, Bcl-2, Bcl-xL). Some 
of them seem to be crucial in determining platinum drugs efficacy, but importance of 
most of them remains unclear. Therefore more work needs to be done to determine to 
which extent these mechanisms influence resistance to platinum drugs and influence 
their efficacy in the pharmacotherapy. 
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6. Abstrakt 
 
Ačkoliv první platinová sloučenina, cisplatina, byla poprvé popsána již v roce 1845, 
její biologická aktivita byla objevena o více než 100 let později. Od té doby je cisplatina 
a její klinicky využívané analogy karboplatina a oxaliplatina široce používána pro léčbu 
mnoha lidských karcinomů. Mezi ně patří zejména ovariální, cervikální, renální a 
nemalobuněčný plicní karcinom, karcinom hlavy a krku, prsu, tlustého střeva, žaludku, 
sarkom a lymfom. Bohužel je léčba často doprovázena vážnými nežádoucími účinky, ze 
kterých nefrotoxicita, periferní neurotoxicita a útlum kostní dřeně patří mezi ty 
nejzávažnější. Další významnou překážkou v jejich klinickém využití je vznik lékové 
rezistence. Tato práce hodnotí možné mechanismy vzniku rezistence na platinové 
sloučeniny. Jsou rozmanité a zahrnují (i) sníženou akumulaci platinových sloučenin 
způsobenou influxními (Aquaporin 9, CTR1, OCT1, OCT2) a efluxními (ATP7A, ATP7B, 
ABCG2) transportéry; (ii) zvýšenou detoxifikaci pomocí thiolových sloučenin 
glutathionu a metallothioneinu; (iii) zvýšenou schopnost opravovat jaderná poškození 
(NER, MMR a homologní rekombinace), zvýšenou toleranci k jaderným poškozením 
(Replicative bypass), inhibici pro-apoptických faktorů (kaspáza-3, -8, Fas a další) a nebo 
zvýšenou expresi inhibitorů apoptózy (Xiap, Bcl-2, Bcl-xL). Některé z těchto 
mechanismů se zdají být pro vznik rezistence na platinová cytostatika klíčové, avšak 
význam většiny z nich je nejasný. Pro objasnění toho, jakou měrou se podílejí na 
rezistenci nádorů vůči platinovým cytostatikům a jak ovlivňují účinnost těchto léčiv v 
protinádorové terapii musí být provedeny další studie.   
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